🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

15 results for “erlotinib” Clear

  1. BEVACIZUMAB, ERLOTINIB

    Fondazione Telethon ETS

    Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. RAMUCIRUMAB, ERLOTINIB

    Eli Lilly Co.

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. erlotinib

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  4. Erlotinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. Erlotinib

    Hoffmann-La Roche

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  6. Erlotinib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  7. Erlotinib

    United Therapeutics Europe Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Erlotinib

    Solid Biosciences

    Leptomeningeal Carcinomatosis

    phase 2 small molecule terminated

    1 trial

  9. Erlotinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. LY2875358, ERLOTINIB

    Eli Lilly Co.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. eribulin mesylate + erlotinib

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  12. erlotinib [Tarceva]

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  13. erlotinib and bexarotene

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial

  14. PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

  15. erlotinib (Tarceva) and bexarotene (Targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources